Moderna experienced a significant stock surge, adding $45 billion to its market value in a single day, following positive Phase 3 trial results for its individualized mRNA cancer vaccine, intismeran, developed with Merck. This success, which brought Moderna's stock to levels not seen since 2024, has led to a collective $92 billion increase in market capitalization across mRNA companies, including a 177% jump for Moderna, nearly 13% for Merck, and 22% for BioNTech.
While analysts like RBC Capital Markets' Trung Huynh and TD Cowen's Tyler Van Buren called the results a "major win" and a "landmark moment," some cautioned against the market's "overly optimistic" response. Leerink Partners analyst Daina Graybosch argued that the market reaction set expectations that will be "difficult to meet," particularly noting that melanoma may be uniquely suited to such a vaccine and that per-patient manufacturing costs could be high. William Blair analyst Myles Minter projected peak annual melanoma sales of $5.4 billion for Moderna from its 50-50 revenue split with Merck.
Despite the enthusiasm, some analysts, including Evercore ISI's Cory Kasimov, suggested that Moderna's new valuation already prices in significantly more conviction than the disclosed data supports. The trial, which combined intismeran with Merck's Keytruda to reduce the risk of melanoma recurrence and spread, did not initially release specific data, leading to calls for caution until more detailed results are presented. While the success validates the underlying mRNA technology and fuels optimism for other ongoing trials in kidney, bladder, and lung cancers, concerns remain about whether the vaccine's actual sales potential and therapeutic impact justify the current market valuation.
